Semisolid topical hormonal compositions and methods for treatment

• US 20030175329A1
• Filed: 10/04/2002
• Published: 09/18/2003
• Est. Priority Date: 10/04/2001
• Status: Abandoned Application

• Current Assignee: Cellegy Pharmaceuticals, Inc.
• Original Assignee: Cellegy Pharmaceuticals, Inc.
• Inventors: Azarnoff, Daniel L., Mak, Vivien H.W.
• Application Number:
  US10/264,850
• Publication Number:
  US 20030175329A1
• Time in Patent Office: Days
• US Class Current: 424/449
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/568 substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/12 Aerosols; Foams A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015

Abstract

Semisolid topical pharmaceutical compositions comprising a therapeutically effective amount of a mammalian hormone and an effective amount of a penetration enhancer and methods for their use are provided. The pharmaceutical compositions and methods for their use can provide blood or plasma levels of the administered hormone within a predetermined or normal range of hormone values. In particular embodiments, the hormone is testosterone or estrogen and the amount to be applied to the skin of the subject is determined according to the weight or body mass index of the subject. The topical composition can be formulated in solutions, creams, lotions, ointments, and gels.

Claims

1. A method for determining the initial dose to administer to a human subject of a semisolid topical composition having a pH value of between about 4 to about 8 and comprising 0.1% to about 2% w/w of a human sex hormone, a penetration-enhancing amount of oleic acid;

a C₁-C₄ alcohol; and

a glycol, said method comprising;

determining the body weight of the subject;

selecting the dose according to a predetermined empirical relationship between the body weight, the applied dosage, and the serum level of the hormone in a reference population at steady state.

2. The method of claim 1, wherein the relationship is between BMI, the applied dosage, and the C_avg serum level of the hormone.

3. The method of claim 1, wherein the hormone is testosterone.

4. The method of claim 1, wherein the hormone is estrogen.

5. The method of claim 1, wherein the serum level is C_min.

6. The method of claim 1, wherein if the subject has a BMI less than 18.5, the initial dose is 2 g gel;

if the subject has a BMI is between 18.5 and 35, the initial dose is 3 g gel;

or if the subject has a BMI greater than 35, the initial dose is 4 g gel.

29. A method of administering a therapeutically effective amount of a mammalian sex hormone to a human subject;

said method comprising;

calculating a dose of a topical composition comprising the sex hormone and a penetration enhancer according to the method of claim 1;

and

administering the dose of the composition to the skin of the subject.

7. A method for determining the dose to administer to a human subject of a semisolid topical composition comprising a therapeutic amount of a mammalian hormone and an effective amount of a penetration enhancer, said method comprising:

determining the weight and height of the subject;

calculating the Body Mass Index (BMI) of the subject;

and adjusting the dose according to the BMI.

8. The method of claim 7 wherein the adjusting is based upon a predetermined empirical relationship between BMI, the amount of the composition applied, and the serum hormone concentration level measured in a reference population at steady state.

9. The method of claim 7, wherein the hormone is a human sex hormone.

10. The method of claim 7, wherein the hormone is an androgen.

11. The method of claim 9, wherein the hormone is an estrogen.

12. The method of claim 10, wherein the hormone is testosterone or a salt or ester thereof.

13. The method of claim 11, wherein the hormone is a pharmaceutically acceptable salt or ester of estrogen or estradiol.

14. The method of claim 7, wherein the hormone is a progestin.

15. The method of claim 14, wherein the hormone is progesterone or a salt or ester of progesterone.

16. The method of claim 7, wherein the enhancer is oleic acid.

17. The method of claim 7, wherein the hormone has a steroid moeity.

18. The method of claim 7, wherein the topical composition has a pH value of between about 4 to about 8 and comprises

a) the hormone in a concentration of about 0.1% to about 2% w/w, and

b) a penetration-enhancing system consisting essentially of (i) a membrane fluidizer comprising oleic acid;

(ii) a C₁-C₄ alcohol; and

(iii) a glycol.

19. The method of claim 17, wherein the hormone is a member selected from the group consisting of testosterone, estradiol, progestin, and derivatives and mixtures thereof.

20. The method of claim 18, wherein the penetration-enhancing system further comprises (iv) a gelling agent.

21. The method of claim 10, wherein the subject is a male with primary or secondary hypogonadism, male sexual desire disorder, male sexual arousal disorder, AIDS, wasting syndrome associated with chronic illnesses, end stage renal disease, chronic fatigue syndrome, Epstein-Barr virus, heart disease, cancer, diabetes, Alzheimer'"'"'s disease, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, or osteoporosis.

22. The method of claim 7, wherein the subject is a female with sexual dysfunction or with a reduced feeling of well-being, AIDS, wasting syndrome associated with chronic illnesses, end stage renal disease, chronic fatigue syndrome, Epstein-Barr virus, heart disease, cancer, diabetes, Alzheimer'"'"'s disease, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, osteoporosis, or Turner'"'"'s Syndrome.

23. The method of claim 8, wherein adjusting the dose increases the dose by an average of about 1-10% for each single unit increase in the BMI for subjects having a BMI value of 30 to 50 kg/m².

24. The method of claim 10, wherein the subject is male and had a pretreatment average serum testosterone level below 300 ng/dl.

25. The method of claim 7, wherein the dose is an initial dose.

26. The method of claim 7, wherein said composition is selected from the group consisting of solutions, creams, lotions, ointments, and gels.

27. The method of claim 26, wherein said composition has a testosterone concentration of about 0.01% to about 5% w/w.

28. The method of claim 7, wherein the dose is a daily dosage.

30. A method of restoring serum sex hormone levels in a human subject to normal levels, said method comprising:

determining the height and weight of the subject;

using the height and weight of the subject to estimate a first dose amount of a topical composition comprising the sex hormone and a penetration enhancer;

applying at least daily to the skin of the subject the composition in the first dose amount;

measuring the level of the sex hormone in the blood of the subject; and

if the blood sex hormone level is below a first predetermined level, treating the subject with a second dose 25 to 100% greater than the first dose amount;

or, if the blood sex hormone level is above or near a second predetermined level, treating the subject with a third dose which is 25 to 75% less than the first dose amount

31. The method of claim 30, wherein the sex hormone is an androgen selected from the group consisting of testosterone, its salts, esters, and derivatives.

32. The method of claim 31, wherein the testosterone is measured two hours after the initial daily application of the first dose amount.

33. The method of claim 31, wherein the testosterone is measured at the blood testosterone steady state.

34. The method of claim 30, wherein the testosterone is measured at least three days after the first application of the composition.

35. The method of claim 30, wherein the topical composition has a pH value of between about 4 to about 8, and comprises:

a) the hormone in a concentration of about 0.1% to about 2% w/w, and

b) a penetration-enhancing system consisting essentially of (i) a membrane fluidizer comprising oleic acid;

(ii) a C₁-C₄ alcohol; and

(iii) a glycol.

36. The method of claim 30, wherein the sex hormone is an androgen or an estrogen.

37. The method of claim 33, wherein the first predetermined level is about 250-350 ng/dl and the second predetermined level is about 1000-1200 ng/dl.

38. A metered device for delivering a topical composition comprising testosterone and a penetration enhancer to a subject, wherein said metered device provides an identical amount of the composition on each administration and wherein the amount administered is determined by the BMI of the subject.

39. The kit comprising:

a pharmaceutical composition comprising a therapeutic amount of a mammalian hormone and an effective amount of a skin penetration enhancer;

a metered dose pump holding said composition in an amount to provide more than one dose;

said pump set to deliver a fixed amount of the pharmaceutical composition when the pump is activated.

40. The kit of claim 39 further comprising instructions on how to activate the pump.

41. The kit of claim 39 further comprising instructions on where to apply the composition to the skin.

42. A method for determining the dose to administer to a human subject of a semisolid topical composition comprising a therapeutic amount of a mammalian hormone and an effective amount of a penetration enhancer, said method comprising:

determining the body weight and height of the subject;

and adjusting the dose according to the body weight.

43. The method of claim 42, wherein the adjusting is based upon a predetermined empirical relationship between body weight, the amount of the composition applied, and the serum hormone concentration level measured in a reference population at steady state.

44. A method of adjusting serum sex hormone levels in a human subject to normal levels, said method comprising:

determining the weight of the subject;

using the weight of the subject to establish a first dose amount of a topical composition comprising the sex hormone and a penetration enhancer wherein the establishing is based upon a predetermined empirical relationship between body weight, the amount of the composition applied, and the serum hormone concentration level measured in a reference population at steady state;

applying at least daily to the skin of the subject the composition in the first dose amount;

measuring the level of the sex hormone in the blood of the subject; and

if the blood sex hormone level is below a first predetermined level treating the subject with a second dose 25 to 100% greater than the first dose amount;

or if the blood sex hormone level is above or near a second predetermined level, treating the subject with a third dose which is 25 to 75% less than the first dose amount.